Economic Burden of Hypertension in the Russian Federation
https://doi.org/10.20996/1819-6446-2020-05-03
Abstract
The prevalence of hypertension in the Russian Federation (RF) has been growing in recent years, which causes significant socio-economic burden.
Aim. To evaluate economic burden of hypertension in the RF in 2016 including direct costs and economic losses caused by decreased labor efficiency.
Material and methods. The calculation included the prevalence of hypertension in the RF and the relative risk of hypertension for cardiovascular diseases (CVD) (including stroke and coronary heart disease), chronic obstructive pulmonary disease (COPD), type 2 diabetes mellitus (DM2), cancer of the trachea, bronchi and lungs, breast and prostate. The calculation included Russian statistics on noncommunicable diseases (NCD) for 2016. Statistical analysis – calculations were performed by Microsoft Excel 10.0
Results. Population attributable risk (PAR) of hypertension in mortality from all CVDs was 34%, in morbidity – 30%, including PAR in mortality from coronary heart disease and stroke 38% and 60%, respectively; the same in morbidity – 28% and 14%, respectively. For DM2 PAR in mortality was 1%, in morbidity – 18%. For COPD PAR in morbidity was ≈24%. PARs in morbidity and mortality for lung, bronchi and trachea cancer were ≈12%, for prostate cancer ≈3%, and for breast cancer 6%. Direct medical costs associated with the analyzed NCDs exceeded 84 billion rubles, direct non-medical costs – over 1.5 billion rubles. In the structure of economic burden, the main part was associated with gross domestic product (GDP) losses due to premature mortality due to hypertension.
Conclusion. The total economic burden associated with hypertension in 2016 amounted to 869936 million rubles that corresponded to 1% of Russian GDP.
Aim. To evaluate economic burden of hypertension in the RF in 2016 including direct costs and economic losses caused by decreased labor efficiency.
Material and methods. The calculation included the prevalence of hypertension in the RF and the relative risk of hypertension for cardiovascular diseases (CVD) (including stroke and coronary heart disease), chronic obstructive pulmonary disease (COPD), type 2 diabetes mellitus (DM2), cancer of the trachea, bronchi and lungs, breast and prostate. The calculation included Russian statistics on noncommunicable diseases (NCD) for 2016. Statistical analysis – calculations were performed by Microsoft Excel 10.0
Results. Population attributable risk (PAR) of hypertension in mortality from all CVDs was 34%, in morbidity – 30%, including PAR in mortality from coronary heart disease and stroke 38% and 60%, respectively; the same in morbidity – 28% and 14%, respectively. For DM2 PAR in mortality was 1%, in morbidity – 18%. For COPD PAR in morbidity was ≈24%. PARs in morbidity and mortality for lung, bronchi and trachea cancer were ≈12%, for prostate cancer ≈3%, and for breast cancer 6%. Direct medical costs associated with the analyzed NCDs exceeded 84 billion rubles, direct non-medical costs – over 1.5 billion rubles. In the structure of economic burden, the main part was associated with gross domestic product (GDP) losses due to premature mortality due to hypertension.
Conclusion. The total economic burden associated with hypertension in 2016 amounted to 869936 million rubles that corresponded to 1% of Russian GDP.
About the Authors
Yu. A. Balanova
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Yulia A. Balanova - MD, PhD, Leading Researcher, Department of Public Health Promotion, National Medical Research Center for Therapy and Preventive Medicine.
Petroverigsky per. 10, Moscow, 101990.
A. V. Kontsevaya
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Anna V. Kontsevaya - MD, PhD, Deputy Director, National Medical Research Center for Therapy and Preventive Medicine.
Petroverigsky per. 10, Moscow, 101990.
A. O. Myrzamatova
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Azalia O. Myrzamatova - MD, PhD, Researcher, Department of Public Health Promotion, National Medical Research Center for Therapy and Preventive Medicine.
Petroverigsky per. 10, Moscow, 101990.
D. K. Mukaneeva
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Dinara K. Mukaneeva - MD, Junior Researcher, Department of Public Health Promotion, National Medical Research Center for Therapy and Preventive Medicine.
Petroverigsky per. 10, Moscow, 101990.
M. B. Khudyakov
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Mihail B. Khudyakov - Leading Engineer, Department of Public Health Promotion, National Medical Research Center for Therapy and Preventive Medicine.
Petroverigsky per. 10, Moscow, 101990.
O. M. Drapkina
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Oxana M. Drapkina - MD, PhD, Professor, Corresponding Member of the Russian Academy of Sciences, Director, National Medical Research Center for Therapy and Preventive Medicine.
Petroverigsky per. 10, Moscow, 101990.
References
1. WHO. A global brief on Hypertension [cited by Dec 1, 2018]. Available from: https://www.who.int/iris/bitstream/10665/79059/1/WHO_DCO_WHD_2013.2_eng.pdf?ua=1.
2. Shalnova S.A., Deev A.D., Balanova Yu.A., et al. Twenty years trends of obesity and arterial hypertension and their association in Russia. Cardiovascular Therapy and Prevention. 2017;16(4):4-10 (In Russ.). DOI:10.15829/1728-8800-2017-4-4-10.
3. Shalnova S., Deev A., Kapustina A., et al. Treatment of hypertension in high-risk patients. Monotherapy or combination? Therapist. 2016;7:17 (In Russ.).
4. Boytsov S.A., Balanova Yu.A., Shalnova S.A., et al. Arterial hypertension among individuals of 25-64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention. 2014;14(4):4-14 (In Russ.). DOI:10.15829/1728-8800-2014-4-4-14.
5. Reis A.F.N., Lima J.C., Beccaria L.M., et al. Hypertension and diabetes-related morbidity and mortality trends in a municipality in the country side of Sao Paulo. Revista Latino-Americana de Enfermagem. 2015;23(6):1157-64. DOI:10.1590/0104-1169.0533.2661.
6. Kim S.H., Park J.H., Lee J.K., et al. Chronic obstructive pulmonary disease is independently associated with hypertension in men: A survey design analysis using nationwide survey data. Medicine. 2017;96(19):e6826. DOI:10.1097/MD.0000000000006826.
7. Kim M.J., Lim N.K., Choi S.J. Hypertension is an independent risk factor for type 2 diabetes: the Korean genome and epidemiology study. Hypertens Res. 2015;38(11):783-9. DOI:10.1038/hr.2015.72.
8. Lindgren A., Pukkala E., Nissinen A., et al. Blood pressure, smoking, and the incidence of lung cancer in hypertensive men in North Karelia, Finland. Am J Epidemiol. 2003;158(5):442-7. DOI:10.1093/aje/kwg179.
9. Han H., Guo W., Shi W. et al. Hypertension and breast cancer risk: a systematic review and meta-analysis. Scientific Reports. 2017;7:44877. DOI:10.1038/srep44877.
10. Liang Z., Xie B., Li J., et al. Hypertension and risk of prostate cancer: a systematic review and meta-analysis. Scientific Reports. 2016;6:31358. DOI:10.1038/srep31358.
11. Heidenreich P.A., Trogdon J.G., Khavjou O.A., et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933-44. DOI: 10.1161/CIR.0b013e31820a55f5
12. Yang L., Wu M., Cui B., et al. Economic burden of cardiovascular diseases in China. Expert Rev Pharmacoecon Outcomes Res. 2008;8(4):349-56. DOI:10.1586/14737167.8.4.349.
13. Li Y., Yang L., Wang L. et al. Burden of hypertension in China: a nationally representative survey of 174,621 adults. Int J Cardiol. 2017;227:516-523. DOI:10.1016/j.ijcard.2016.10.110.
14. Wang Y., Peng X., Nie X., et al. Burden of hypertension in China over the past decades: systematic analysis of prevalence, treatment and control of hypertension. Eur J Prev Cardiol. 2016;23(8):792-800. DOI:10.1177/2047487315617105.
15. Lewington S., Lacey B., Clarke R., et al. The burden of hypertension and associated risk for cardiovascular mortality in China. JAMA. 2016;176(4):524-32. DOI:10.1001/jamainternmed.2016.0190.
16. Burykin I.M., Aleeva G.N., Khafizianova R.K. The burden of hypertension at the regional level. Health and Education Millennium. 2017;19(8):76-80 (In Russ.).
17. Shulpina N.Yu., Erugina M.V., Sazanova G.Yu., Krom I.L. Issues on optimization of primary health care for working patients with diagnosed hypertension. Saratov Journal of Medical Scientific Research. 2017;13(1):7-9. (In Russ.).
18. Zhuravlev D.A., Bochanova E.N., Bogdanov V.V. Analysis of treatment cost of essential hypertension in the Krasnoyarsk region in terms of drug insurance. Siberian Medical Review. 2014;4(88):82-5 (In Russ.).
19. Research organizing committee of the ESSE-RF project. Epidemiology of cardiovascular diseases in different regions of Russia (ESSE-RF). The rationale for and design of the study. Russian Journal of Preventive Medicine and Public Health. 2013;6:25-34 (In Russ.). DOI:10.20333/25000136-2014-4-82-85.
20. Shalnova S. A., Deev A. D., Balanova Yu. A., et al. Trends of arterial hypertension in russia: is there a progress in prescription of antihypertensive therapies? (results of studies in 1993-2013). Russian Heart Journal. 2015;14(6):389-96 (In Russ.) DOI:10.18087/rhj.2015.6.2145.
21. Kontsevaya A.V., Drapkina O.M., Balanova Y.A., et al. Economic Burden of Cardiovascular Diseases in the Russian Federation in 2016. Rational Pharmacotherapy in Cardiology. 2018;14(2):156-66 (In Russ.). DOI:10.20996/1819-6446-2018-14-2-156-166.
22. Kontsevaya A.V., Balanova Y.A., Imaeva A.E., et al. Economic Burden of Hypercholesterolemia in the Russian Federation. Rational Pharmacotherapy in Cardiology 2018;14(3):393-401 (In Russ.). DOI:10.20996/1819-6446-2018-14-3-393-401.
23. Dedov I.I., Kontsevaya A.V., Shestakova M.V., et al. Economic evaluation of type 2 diabetes mellitus burden and its main cardiovascular complications in the Russian Federation Diabetes Mellit. 2016;19(6):518-27 (In Russ.). DOI:10.14341/DM8153.
24. Kontsevaya A.V., Mukaneyeva D.K., Balanova Y.A., et al. Economic burden of respiratory diseases and chronic obstructive pulmonary disease in Russian Federation, 2016. Pulmonology. 2019;29(2):159-66 (In Russ.). DOI:10.18093/0869-0189-2019-29-2-159-166.
25. Balanova Yu.A., Kontsevaya A.V., Myrzamatova A.O., et al. Economic burden associated with excess salt consumption in the Russian Federation in 2016. Cardiovascular Therapy and Prevention. 2019;4:62-8 (In Russ.).
26. Altman D. G. Practical statistics for medical research. London: Chapman and Hall; 1991.
27. Letter No. 11-7 / 10 / 2-8080 of the Ministry of Health of the Russian Federation, ФФОМС № 13572 / 26-2 / and on 21.11.2017 "On methodological recommendations on how to pay for medical care from the means of compulsory medical insurance" (In Russ.).
28. Kaprin A.D., Starinsky V.V., Petrova G.V. Malignancies In Russia In 2016 (Morbidity and Mortality). Moscow: MNIOI im. P.A. Gertsena - filial FGBU «NMITS radiologii»; 2018 (In Russ.).
29. Krysanov I.S., Sveshnikova N.D., Tsfasman F.M. Cost-effectiveness of drugs for smoking sessation in Russia. Medical Technologies. Assessment and Choice. 2011;2(4):16-22 (In Russ.).
30. Ignatyeva V.I., Gretsova O.P., Stenina M.B., et al. Social and Economic Burden of Breast Cancer in the Russian Federation. Medical Technologies. Assessment and Choice. 2016;4(26):32-49 (In Russ.).
31. Derkach E.V., Ignatieva V.I., Shirokorad V.I., et al. Social and economic burden of prostate cancer in Russia Medical Technologies. Assessment and Choice. 2012;2(8):34-45 (In Russ.).
32. The number of persons first recognized as disabled. Russian Ministry of Labor data, calculation by Rosstat 1995-2017 [cited by Dec 11, 2018]. Available from: https://www.gks.ru/free_doc/new_site/population/zdrav/zdra42_bd.htm (In Russ.).
33. The Russian Fertility and Mortality database (RusFMD) [cited by Dec 11, 2018]. Available from: http://demogr.nes.ru/ru/demogr_indicat/data_description (In Russ.).
34. Franklin S.S., Lopez V.A., Wong N.D., et al. Clinical perspective. Circulation. 2009;119(2):243-250.Circulation. 2009;119:243-50. DOI:10.1161/CIRCULATIONAHA.108.797936.
35. da Silva T.L. N., Klein C.H., da Rocha Nogueira A., et al. Cardiovascular mortality among a cohort of hypertensive and normotensives in Rio de Janeiro-Brazil-1991-2009. BMC Public Health. 2015;15(1):623. DOI: 10.1186/s12889-015-1999-4.
36. Malyutina S.K., Simonova G.I., Gafarov V.V., et al. Prospective study of hypertension impact on the risk of cardiovascular events Bulletin of the Siberian Branch of the Russian Academy of Medical Sciences. 2003;4(110):6-10 (In Russ.).
37. Konstantinov V.V., Deev A.D., Balanova Iu.A., et al. The cardiovascular risk profile and its contribution to survival in Moscow men and women aged 35-64 years. Profilakticheskaya Meditsina. 2013;16(1):3-7 (In Russ.).
38. Shalnova S.A., Deev A.D., Vihireva O.V., et al. The prevalence of hypertension in Russia. Awareness, treatment and control. Profilaktika Zabolevanij i Ukreplenie Zdorov'ja. 2001;2:3-7 (In Russ.).
39. Gorgui J., Gorshkov M., Khan N., et al. Hypertension as a risk factor for ischemic stroke in women. Can J Cardiol. 2014;30(7):774-82. DOI:10.1016/j.cjca.2014.01.007.
40. Turin T.C., Okamura T., Afzal A.R. et al. Hypertension and lifetime risk of stroke. J Hypertens. 2016;34(1):116-22. DOI:10.1097/HJH.0000000000000753.
41. Shalnova SA. Epidemiology of arterial hypertension in Russia: a portrait of a patient. Arterial Hypertension. 2008;2(2):5-10 (In Russ.).
42. Forouzanfar M. H., Liu P., Roth G. A., et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015. JAMA. 2017;317(2):165-82. DOI:10.1001/jama.2016.19043.
43. Arredondo A., Avilés R. Hypertension and its effects on the economy of the health system for patients and society: suggestions for developing countries. Am J Hypertens. 2014;27(4):635-6. DOI:10.1093/ajh/hpu010.
44. Balanova Y.A., Kontsevaya A.V., Imaeva A.E., et al. Economic losses due to low coverage of lipid-lowering therapy in patients with cardiovascular diseases in the Russian Federation. Rational Pharmacotherapy in Cardiology. 2018;14(5):716-24 (In Russ.). DOI:10.20996/1819-6446-2018-14-5-716-724.
45. Wang G., Grosse S.D., Schooley M.W. Conducting Research on the Economics of Hypertension to Improve Cardiovascular Health. Am J Prev Med. 2017;53(6):S115-7. DOI:10.1016/j.amepre.2017.08.005.
46. Zhang D., Wang G., Zhang P. Medical Expenditures Associated With Hypertension in the U.S., 2000-2013. Am J Prev Med. 2017;53(6):S164-71. DOI:10.1016/j.amepre.2017.05.014.
47. Andreadis A.E. Hypertension and Cardiovascular Disease. Cham, Switzerland: Springer; 2016. DOI:10.1007/978-3-319-39599-9.
48. Mennini F.S., Marcellusi A., von der Schulenburg J.M.G., et al. Cost of poor adherence to anti-hypertensive therapy in five European countries. Eur J Heal Econ. 2015;16(1):65-72. DOI:10.1007/s10198-013-0554-4
49. Konradi A.O., Polunicheva E.V. Lack of adherence to treatment of hypertension: Causes and correction. Arterial'naja Gipertenzija. 2004;10(3):137-43 (In Russ.).
Review
For citations:
Balanova Yu.A., Kontsevaya A.V., Myrzamatova A.O., Mukaneeva D.K., Khudyakov M.B., Drapkina O.M. Economic Burden of Hypertension in the Russian Federation. Rational Pharmacotherapy in Cardiology. 2020;16(3):415-423. (In Russ.) https://doi.org/10.20996/1819-6446-2020-05-03
Views: 811
Email this article 